Department of dermatology CHU Limoges, National Reference Center for Bullous Diseases, Limoges, France
Deparment of Dermatology CH Brive, France
Eur J Dermatol. 2022 May 1;32(3):368-372. doi: 10.1684/ejd.2022.4270.
Gliptins, also called dipeptidyl peptidase-4 inhibitors, have been incriminated in the development of bullous pemphigoid (BP). To date, there are no recommendations regarding the therapeutic approach for BP during gliptin intake.
The aim of this retrospective study was to evaluate the evolution of BP after three months relative to continuation or discontinuation of gliptin.
MATERIALS & METHODS: From a series of 372 patients with BP, 40 taking gliptin were included (January 2009 to December 2019). The primary endpoint was complete response, three months after BP diagnosis based on gliptin continuation or discontinuation. The secondary endpoints were complete response after one month and six months.
Of BP patients, 67.5% were taking vildagliptin. BP was diagnosed at a mean period of 28.8 months after gliptin initiation. Gliptin was continued and discontinued each in 20 patients. Three months after diagnosis, patients who stopped gliptin had a significatively better clinical status (p = 0.0006). Thirteen patients had complete response when gliptin was stopped, compared to one patient when gliptin was continued. This difference was maintained after six months (p = 0.0031). There was no difference between the treatments received by patients who stopped gliptin and those who continued treatment (p = 0.7515).
In this retrospective study, two groups were compared; one that continued gliptin and the other that stopped the drug. The results obtained suggest that stopping gliptin allows for a complete response rate at three months and six months, whereas gliptin maintenance did not allow for complete response.
Gliptins，也称为二肽基肽酶-4 抑制剂，已被牵连到大疱性类天疱疮 (BP) 的发展中。迄今为止，对于Gliptin 摄入期间 BP 的治疗方法尚无建议。
本回顾性研究的目的是评估 BP 诊断后三个月继续或停止使用 Gliptin 对其的影响。
从 372 例 BP 患者中，纳入了 40 例正在服用 Gliptin 的患者（2009 年 1 月至 2019 年 12 月）。主要终点是根据 BP 诊断后继续或停止使用 Gliptin 三个月后的完全缓解。次要终点是一个月和六个月后的完全缓解。
BP 患者中，67.5%服用维格列汀。BP 在 Gliptin 开始后平均 28.8 个月被诊断。20 例患者继续和停止使用 Gliptin。诊断后三个月，停止使用 Gliptin 的患者临床状况明显更好（p = 0.0006）。停止使用 Gliptin 的 13 例患者完全缓解，而继续使用 Gliptin 的患者只有 1 例。六个月后仍保持这种差异（p = 0.0031）。停止使用 Gliptin 的患者和继续治疗的患者接受的治疗之间没有差异（p = 0.7515）。
在这项回顾性研究中，比较了继续使用 Gliptin 和停止使用该药的两组患者。结果表明，停止使用 Gliptin 可在三个月和六个月时达到完全缓解率，而维持 Gliptin 则不能达到完全缓解。
